Endocrinol Metab.  2011 Dec;26(4):295-296. 10.3803/EnM.2011.26.4.295.

The Effects of Combination Therapy of Cathepsin K Inhibitor and PTH on Change of Bone Mineral Density in Animal Model of Osteoporosis

• Rhee Y

• KMID: 2169258
• DOI: http://doi.org/10.3803/EnM.2011.26.4.295

Abstract

No abstract available.

MeSH Terms

Animals
Bone Density
Cathepsin K
Cathepsins
Models, Animal
Osteoporosis
Cathepsin K
Cathepsins

Reference

1. Cusano NE, Bilezikian JP. Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr Med Res Opin. 2011. 27:1705–1707.

2. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003. 349:1207–1215.

3. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003. 349:1216–1226.

4. Johnston S, Andrews S, Shen V, Cosman F, Lindsay R, Dempster DW, Iida-Klein A. The effects of combination of alendronate and human parathyroid hormone (1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology. 2007. 148:4466–4474.

5. Yang X, Chan YH, Muthukumaran P, Dasde S, Teoh SH, Lee T. Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study. Bone. 2011. 48:1154–1163.

6. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005. 20:1905–1911.

7. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010. 25:937–947.

8. Lee SH, Koh JM, Lee YS, Kim BJ, Choi JY, Kim GS. The effects of combination therapy of cathepsin K inhibitor and PTH on change in bone mineral density in animal model of osteoporosis. Endocrinol Metab. 2011. 26:303–309.

9. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011. 7:447–456.

10. Cosman F, Eriksen EF, Recknor C, Miller PD, Gua Mille N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011. 26:503–511.